Exploration and utilization of exosome biomarkers and their related functions provide the possibility for the diagnosis and treatment of post-stroke cognitive impairment (PSCI). To identify the new diagnostic and prognostic biomarkers of plasma exosome were uzed label-free quantitative proteomics and biological information analysis in PSCI patients. Behavioral assessments were performed, including the Mini-Mental Status Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the Barthel index, the Morse Fall Seale (MFS) between control group ( n = 10) and PSCI group ( n = 10). The blood samples were collected to analyse the biomarker and differentially expressed proteins of plasma exosome using label-free quantitative proteomics and biological information. The exosomes marker proteins were determined by Western blot. The exosome morphology was observed by transmission electron microscopy. The scores of MMSE and MoCA were significantly decreased in the PSCI group. The PT% and high-density lipoprotein decreased and the INR ratio increased in PSCI group. The mean size of exosome was approximately 71.6 nm and the concentration was approximately 6.8E+7 particles/mL. Exosome proteomics identified 259 differentially expressed proteins. The mechanisms of cognitive impairment are related to regulate the degradation of ubiquitinated proteins, calcium dependent protein binding, cell adhesive protein binding, formation of fibrin clot, lipid metabolism and ATP-dependent degradation of ubiquitinated proteins in plasma exosome of PSCI patients. Plasma levels of YWHAZ and BAIAP2 were significantly increased while that of IGHD, ABCB6 and HSPD1 were significantly decreased in PSCI patients. These proteins might be target-related proteins and provide global insights into pathogenesis mechanisms of PSCI at plasma exosome proteins level.
Background Recently, the plasma exosome biomarkers of post-stroke cognitive impairment (PSCI) have been brought into focus. Exploration and utilization of exosome biomarkers and their related functions provided the possibility for the diagnosis and treatment of PSCI. Aims To identify for new diagnostic and prognostic biomarkers of plasma exosome using label-free quantitative proteomics and biological information analysis in PSCI patients. Methods A series of behavioral assessments were performed, including the Mini-Mental Status Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the Barthel index, the Morse Fall Seale (MFS) beteen control group (n = 10) and PSCI group (n = 10). The blood samples were collected to analyse the biomarker and differentially expressed proteins of plasma exosome using label-free quantitative proteomics and biological information. The exosomes marker proteins were determined by Western blot. The exosome morphology was observed by transmission electron microscopy. Results The scores of MMSE and MoCA were significantly decreasd in the PSCI group. The PT% and high-density lipoprotein decreasd and the INR ratio increasd in PSCI group. The mean size of exosome was approximately 71.6 nm and the concentration was approximately 6.8E + 7 particles/mL. Exosome proteomics identificated 259 differentially expressed proteins, including 131 up-regulated proteins and 128 down-regulated proteins. The mechanisms of cognitive impairment are related to up-regulation of degradation of ubiquitinated proteins, calcium dependent protein binding, cytoskeleton reorganization, platelet aggregation and down-regulation of cell adhesive protein binding, formation of fibrin clot, complement activation, lipid metabolism and ATP-dependent degradation of ubiquitinated proteins in plasma exosome of PSCI patients. Plasma levels of YWHAZ and BAIAP2 were significantly increased while that of IGHD, ABCB6 and HSPD1 were significantly decreased in PSCI patients. Conclusion These proteins might be target-related proteins and provide global insights into pathogenesis mechanisms of PSCI at plasma exosome proteins level.
Background Recently, the plasma exosome biomarkers of post-stroke cognitive impairment (PSCI) have been brought into focus. Exploration and utilization of exosome biomarkers and their related functions provided the possibility for the diagnosis and treatment of PSCI. Aims To identify for new diagnostic and prognostic biomarkers of plasma exosome using label-free quantitative proteomics and biological information analysis in PSCI patients. Methods A series of behavioral assessments were performed, including the Mini-Mental Status Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the Barthel index, the Morse Fall Seale (MFS) beteen control group (n = 10) and PSCI group (n = 10). The blood samples were collected to analyse the biomarker and differentially expressed proteins of plasma exosome using label-free quantitative proteomics and biological information. The exosomes marker proteins were determined by Western blot. The exosome morphology was observed by transmission electron microscopy. Results The scores of MMSE and MoCA were significantly decreasd in the PSCI group. The PT% and high-density lipoprotein decreasd and the INR ratio increasd in PSCI group. The mean size of exosome was approximately 71.6 nm and the concentration was approximately 6.8E + 7 particles/mL. Exosome proteomics identificated 259 differentially expressed proteins, including 131 up-regulated proteins and 128 down-regulated proteins. The mechanisms of cognitive impairment are related to up-regulation of degradation of ubiquitinated proteins, calcium dependent protein binding, cytoskeleton reorganization, platelet aggregation and down-regulation of cell adhesive protein binding, formation of fibrin clot, complement activation, lipid metabolism and ATP-dependent degradation of ubiquitinated proteins in plasma exosome of PSCI patients. Plasma levels of YWHAZ and BAIAP2 were significantly increased while that of IGHD, ABCB6 and HSPD1 were significantly decreased in PSCI patients. Conclusion These proteins might be target-related proteins and provide global insights into pathogenesis mechanisms of PSCI at plasma exosome proteins level.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.